Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.21 EUR
Change Today +0.011 / 0.50%
Volume 0.0
RYIN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:27 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

sunesis pharmaceuticals inc (RYIN) Snapshot

Open
€2.24
Previous Close
€2.20
Day High
€2.27
Day Low
€2.21
52 Week High
08/28/14 - €6.47
52 Week Low
10/13/14 - €0.78
Market Cap
150.0M
Average Volume 10 Days
233.3
EPS TTM
--
Shares Outstanding
67.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUNESIS PHARMACEUTICALS INC (RYIN)

Related News

No related news articles were found.

sunesis pharmaceuticals inc (RYIN) Related Businessweek News

No Related Businessweek News Found

sunesis pharmaceuticals inc (RYIN) Details

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. The company was founded in 1998 and is headquartered in South San Francisco, California.

39 Employees
Last Reported Date: 03/12/15
Founded in 1998

sunesis pharmaceuticals inc (RYIN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $469.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $378.8K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2013.

sunesis pharmaceuticals inc (RYIN) Key Developments

Sunesis Pharmaceuticals, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:30 PM

Sunesis Pharmaceuticals, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:30 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

Sunesis Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended Dec. 31, 2014

Sunesis Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended Dec. 31, 2014. For the quarter, the company reported total revenues of $896,000 compared to $1,989,000 a year ago. Loss from operations was $11,154,000 compared to $7,592,000 a year ago. Diluted net loss was $1,323,000 or $0.02 per diluted share compared to $8,257,000 or $0.15 per diluted share a year ago. Cash used in operations was $9.0 million compared to $9.7 million a year ago. For the year, the company reported total revenues of $5,734,000 compared to $7,956,000 a year ago. Loss from operations was $45,043,000 compared to $31,773,000 a year ago. Diluted net loss was $46,894,000 or $0.76 per diluted share compared to $34,598,000 or $0.66 per diluted share a year ago. Revenue in each period was primarily due to deferred revenue recognized related to the royalty agreement with Royalty Pharma. Cash used in operations was $43.2 million compared to $37.4 million a year ago.

Sunesis Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 12, 2015

Sunesis Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RYIN:GR €2.21 EUR +0.011

RYIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeurogesX Inc $0.01 USD +0.0025
POZEN Inc $7.69 USD +0.01
View Industry Companies
 

Industry Analysis

RYIN

Industry Average

Valuation RYIN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.2x
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit www.sunesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.